Use of Crotalidae equine immune F(ab’)2 antivenom for treatment of an Agkistrodon envenomation
Name:
Successful Use of Anavip for ...
Size:
218.0Kb
Format:
PDF
Description:
Final Accepted Manuscript
Affiliation
Arizona Poison and Drug Information Center, University of ArizonaIssue Date
2021-03-11
Metadata
Show full item recordPublisher
Taylor and Francis Ltd.Citation
Wilson, B. Z., Larsen, J., Smelski, G., Dudley, S., & Shirazi, F. M. (2021). Use of Crotalidae equine immune F (ab’) 2 antivenom for treatment of an Agkistrodon envenomation. Clinical Toxicology, 1-5.Journal
Clinical ToxicologyRights
© 2021 Copyright - All Rights Reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Introduction: Anavip (F(ab’)2AV) is a lyophilized F(ab’)2 immunoglobulin fragment derived from horses immunized with venom from Bothrops asper and Crotalus durissus. It was approved by the FDA in 2015 for treatment of North American rattlesnake envenomation but not for Agkistrodon envenomation. Published data regarding the efficacy and safety of Anavip in treating Agkistrodon envenomations is limited. We present a case of a patient treated with Anavip after confirmed Agkistrodon laticinctus envenomation. Case details: A 77 year-old man was bitten on his fifth finger by a captive A. laticinctus. He was taken to a local emergency department where he received a 10 vial initial dose of F(ab’)2AV for pain and swelling and was transferred. At the receiving facility, his pain had improved and his swelling had not progressed. Over the next 30 h, his platelets declined to 132,000/mm3 and he received an additional 4 vials of F(ab’)2AV. The remainder of his course was unremarkable with complete recovery by 3 months. Discussion: This case provides an additional published datapoint on the use of this F(ab’)2AV in the treatment of envenomation by Agkistrodon. © 2021 Informa UK Limited, trading as Taylor & Francis Group.Note
12 month embargo; first published online 11 March 2021ISSN
1556-3650EISSN
1556-9519Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1080/15563650.2021.1892718
